A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
NCT06605703 on ClinicalTrials.gov · last registry update 2026-04-13
An unusually large phase 4: 226 participants, more than double the 72 typical for the stage. The sponsor logged completion for 5 February 2026. Primary outcome, as filed: Percent body weight change at 12 weeks. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- WW International Inc
- Sponsor type
- Industry
- Enrollment
- 226
- Started
- 2024-09-18
- Primary completion
- 2026-02-05 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent body weight change at 12 weeks
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.